to Content
Header Image

Dr. Hartmut EHRLICH Vice President Global Research & Development, Baxter BioScience, Wien


1978-1985 Medical School: Justus-Liebig-University, Giessen, Germany
1985-1987 Department of Hematology-Oncology Indiana University, Indianapolis, Indiana, USA
1988-1990 Department of Molecular Biology, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands
1990-1991 Max-Planck-Gesellschaft, Kerckhoff-Clinic for Cardiology/Cardiovascular Surgery
1991-1995 Sandoz Pharma (now Novartis Pharma)
since 1995 Baxter Healthcare Corporation
since 2006 Vice President Global Research and Development Baxter BioScience


American Society of Hematology (ASH)
International Society for Thrombosis and Hemostasis (ISTH)
Gesellschaft für Thrombose und Hämostaseforschung (GTH)
Internatonal Society for Infectious Diseases (ISID)


Ehrlich, H. J. et al.: Recombinant human protein C derivatives: Altered response to calcium resulting in enhanced activation by thrombin. EMBO J. 9: 2367 2373, 1990
Ehrlich, H. J. et al.: Thrombin neutralizes plasminogen activator inhibitor 1 (PAI 1) that is complexed with vitronectin in the endothelial cell matrix. J. Cell Biol. 115: 1773-1781, 1991
Ehrlich, H. J. et al.: Safety and Immunogenicity of the Modified Adult Tick-Borne Encephalitis Vaccine FSME-IMMUN: Results of Two Large Phase 3 Clinical Studies. Vaccines 24: 5256-5263, 2006
Ehrlich H. J. et al.: A Clinical Trial of a Whole-Virus H5N1 Vaccine Derived from Cell Culture. N Engl J Med; 358: 2573-84, 2008


Doctoral Thesis: Summa cum laude, 1986
ECFMG Certificate (US Medical Exam), 1986
Indiana University School of Medicine, Fellow, 1987
Symposium Meningitis in Children, 12. ICID (Lisbon), Chairman and Speaker, 2006